Aymeric Sallin
Founder and CEO @ NanoDimension
San Francisco, United States
Aymeric Sallin is a Series B investor at NanoDimension in San Francisco focused on Biotechnology and Medical. Aymeric Sallin is the Founder and Managing Director of NanoDimension.Aymeric has led investments in Crocus Technology, Xtellus, and Selecta Biosciences and currently represents NanoDimension on the Board of Crocus Technology and Selecta Biosciences.Aymeric has received the "NSTI Fellow Award" for outstanding contributions to theadvancement of the international nanotechnology community.Prior to NanoDimension, Aymeric was a strategy consultant at Bain & Company focusing on the high-tech industry.Aymeric received a Masters Degree in Physical Engineering from the Federal Institute of Technology (EPFL) in Lausanne, Switzerland and currently serves on the Advisory Board of the Physics Department.
- Total investments:
- 21
- Last investment:
- Lead investor:
- 29%
Last updated:
For AI agents: llms.txt
Industries Aymeric Sallin invests in
Stages Aymeric Sallin invests in
Countries Aymeric Sallin invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (14%)
- Medical 2 (10%)
- Electronics 2 (10%)
- Health Care 2 (10%)
- Software 1 (5%)
Stage
- Series B 2 (10%)
- Series D 2 (10%)
- Series E 2 (10%)
- Funding Round 2 (10%)
- Series A 1 (5%)
Country
- United States 5 (24%)
- Switzerland 1 (5%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| H55 is developing certified technology solutions to make aviation clean, quite, efficient, affordable and ultimative autonomous through the use of electric propulsion systems and sensor technology. | Venture - Series Unknown / Feb 20, 2018 | ||
| Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities. | $30M / Series D / Feb 02, 2017 | ||
| Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.Itwas founded in 2008 and is headquartered in Watertown, Massachusetts. | $38M / Series E / Sep 08, 2015 | ||
| Crocus Technology SA provides magnetic random access memory products and technologies for the semiconductor and electronic systems industries. It offers its products for use in telecommunication, networking, storage, computing, and handheld applications. | $21M / Series E / Jun 16, 2015 | ||
| Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities. | $21M / Series B / Jan 07, 2015 | ||
| Selecta Biosciences is a biopharmaceutical company developing the first generation of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Their proprietary product platform technology combines recent advances in immunobiology with cutting-edge nanotechnology to develop targeted immunomodulatory nanoparticles.Itwas founded in 2008 and is headquartered in Watertown, Massachusetts. | $20M / Private Equity / Oct 15, 2014 | ||
| Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities. | $21M / Series B / Dec 24, 2013 | ||
| View is the leader in smart building technologies that transform buildings to improve human health and experience, reduce energy consumption and carbon emissions, and generate additional revenue for building owners. View Smart Windows use artificial intelligence to automatically adjust in response to the sun, increasing access to natural light andunobstructed views while eliminating the need for blinds and minimizing heat and glare. Every View installation includes a cloud-connected smart building platform that can be extended to reimagine the occupant experience. View is installed and designed into over 90 million square feet of buildings, including offices, hospitals, airports, educational facilities, hotels, and multifamily residences. | $12.6M / Nov 05, 2013 | ||
| View is the leader in smart building technologies that transform buildings to improve human health and experience, reduce energy consumption and carbon emissions, and generate additional revenue for building owners. View Smart Windows use artificial intelligence to automatically adjust in response to the sun, increasing access to natural light andunobstructed views while eliminating the need for blinds and minimizing heat and glare. Every View installation includes a cloud-connected smart building platform that can be extended to reimagine the occupant experience. View is installed and designed into over 90 million square feet of buildings, including offices, hospitals, airports, educational facilities, hotels, and multifamily residences. | $55M / Series D / Jun 25, 2012 | ||
| Tarveda Therapeutics is a developer of miniature drug conjugates designed for the treatment of patients with a wide range of solid tumors. The company's HSP90 targeted drug conjugate platform with lead drug candidate PEN-866 selectively binds in tumors to the activated form of Heat Shock Protein 90 (HSP90) and releases its potent topoisomerase1 inhibitor payload, SN38 and it also develops a miniature drug conjugate in clinical evaluation for the treatment of patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine, small cell lung and other solid tumors, enabling companies to extend the lives of patients with hard to treat cancers while minimizing potential toxicities. | $2.8M / Series A / Jan 06, 2012 | ||
| See all 21 investments → | |||
Co-Investors
About NanoDimension
NanoDimension is a leading venture capital firm investing in disruptive technologies in and at the convergence of the life and physical sciences. We focus on early stage opportunities in the US and Europe led by exceptional entrepreneurs. NanoDimension’s investment team takes an active approach to building portfolio companies, leveraging ourexpertise and network to find and build companies with innovative solutions to critical global problems.
NanoDimension Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Jonathan Nicholson
Director
|
|||
|
Aymeric Sallin
Founder and CEO
|
|||
Colin Walsh
Vice President
|
|||
Eric Moessinger
Partner
|
|||
Kirill Kuzmichev
Principal
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Aymeric Sallin invest in?
Aymeric Sallin invests primarily in Biotechnology, Medical and Electronics startups, most often at Series B and Series D stage. Most of the 21 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Aymeric Sallin?
Public channels for Aymeric Sallin include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Aymeric Sallin last invest?
The most recent investment recorded for Aymeric Sallin closed in Feb 2018. Shizune tracks 21 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
